Xcout Intel
Galecto Inc. competitors & alternatives
The 12 closest competitors and alternatives to Galecto Inc. among biotechnology companies — ranked by similarity to what Galecto Inc. actually does, not by market-cap band.
Subscribe to see Galecto Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Galecto Inc.
Galecto is a clinical-stage biotechnology company focused on developing novel drugs for the treatment of fibrosis, inflammation, and other serious human diseases. Incorporated in the US with operating headquarters in Copenhagen, Denmark, the company is backed by investors such as Novo Holdings and OrbiMed.
Galecto Inc. at a glance
Galecto Inc. is a biotechnology company headquartered in Denmark. It has raised at least $713.3M across the 4 funding rounds on record. Its most recent funding round raised $285M in November 2025. Xcout tracks 23 named people at Galecto Inc., including Hans T. Schambye (President & Chief Executive Officer).
Galecto Inc. leadership
- Hans T. SchambyePresident & Chief Executive Officer
- Jennifer JarrettChief Executive Officer & Board Director
- Sherwin SattarzadehChief Operating Officer
- Becker HewesChief medical Officer
- Jim BakerChief Corporate Affairs Officer
- Brian BurkavageSenior Vice President, Finance
17 more named people on record for Galecto Inc., with roles, board committees and tenure — see the full roster →
Galecto Inc. funding rounds
At least $713.3M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $285M | — | |
| Series C | $285M | 14 named | |
| — | $64.2M | 14 named | |
| SEC Form D filing | $79.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Galecto Inc. competitors
Ranked by semantic similarity — how close each company is to Galecto Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Galecto Biotech is a biotechnology company developing small-molecule inhibitors targeting galectin proteins and related pathways, with applications in fibrotic diseases and cancer. Its products are intended for patients and healthcare providers, particularly in areas with limited treatment options.
Biotech
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Similar biotechnology company
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Biotech
Chemomab is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. Based in Tel Aviv, Israel, the company builds its treatments on unique scientific insights.
Similar biotechnology company
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Similar biotechnology company
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Similar biotechnology company
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Similar biotechnology company
Forward Pharma A/S is a clinical-stage biotechnology company driven by research and discovery, with headquarters located in Denmark.
Biotech
Calliditas Therapeutics AB is a commercial-stage biopharma company based in Stockholm, Sweden. It focuses on developing and commercializing pharmaceutical products.
Similar biotechnology company
MDI Therapeutics, Inc. is a pharmaceutical company headquartered in Novi, Michigan. The company specializes in researching and developing novel therapeutics for the treatment of fibrosis and related fibrotic diseases.
Similar biotechnology company
4F Biotech is a biotechnology firm focused on developing innovative therapeutic approaches, screening platforms, and diagnostic tools to combat fibrosis and inflammatory processes.
Similar biotechnology company
Alentis Therapeutics is a Swiss biotechnology company developing antibody-based medicines that target Claudin-1 (CLDN1), a protein involved in tumor biology and tissue fibrosis. Its therapies are intended for patients with solid tumors and fibrotic diseases, including liver and other organ fibrosis.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Galecto Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Galecto Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →